Tag: non-Hodgkin lymphoma
First Patients Dosed with Combination of Loncastuximab Tesirine + Ibrutinib in...
Diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) are two distinct subtypes of non-Hodgkin lymphoma (NHL). These hematological malignancies are associated with...
15th ICML: Camidanlumab Tesirine Shows High Overall Response Rate in R/R...
During the International Conference on Malignant Lymphoma (ICML), one of the must-attend events for the scientific community involved in the study and treatment of...
Polatuzumab Vedotin Demonstrates Clinical Efficacy Across a Range of Diffuse Large...
Polatuzumab vedotin (DCDS4501A), a novel, targeted anti-cancer agent being developed by Genentech/Roche, is a first-in-class anti-CD79b antibody-drug conjugate or ADC currently being investigated for...
Interim Phase I Data from Camidanlumab Tesirine (ADCT-301) Shows Encouraging Preliminary...
Clinical data from two ongoing Phase I clinical trials evaluating camidanlumab tesirine, also known as ADCT-301* or "Cami-T", in important subtypes of lymphoma and...
Long-Term Data Continues to Support Development Strategy to Establish Brentuximab Vedotin...
Final data from the pivotal phase II trial with brentuximab vedotin (Adcetris®; Seattle Genetics/Takada) in relapsed* or refractory** (r/r) systemic anaplastic large cell lymphoma (sALCL)...
U.S. FDA Grants Priority Review for Brentuximab Vedotin in Cutaneous T-Cell...
The United States Food and Drug Administration (FDA) has accepted for filing a supplemental Biologics License Application (BLA) based on data from the Phase...
Data Confirms STRO-001 Eradicates B-Cell Hematologic Malignancies and Prolongs Survival
STRO-001, an antibody-drug conjugate or ADC targeting the CD74 cell surface protein in hematologic B-cell malignancies, being developed by Sutro Biopharma, has shown to...
Updates from the 14th International Conference on Malignant Lymphoma (ICML)
Since the inaugurational meeting in 1981, the International Conference on Malignant Lymphoma (ICML), traditionally takes place in Lugano, Switzerland, has become one of the...
First Clinical Data from ADCT-402 Demonstrates Encouraging Antitumor Activity in r/r...
The first clinical data from an ongoing Phase I clinical trial evaluating ADCT-402 for the treatment of relapsed or refractory non-Hodgkin’s lymphoma has been...
Debiopharm Acquires Phase II IMGN529 from ImmunoGen
Debiopharm International, a Swiss biopharmaceutical company, has confirmed that it has acquired ImmunoGen's IMGN529, also known as Debio 1562 or naratuximab emtansine, a clinical-stage anti-CD37 antibody-drug...
